research Alopecia Areata Clinical Trial Enrollment and Retention Outcome Factors Among Underrepresented Ethnic and Racial Groups: A Cross-Sectional Study
Clinical trials for alopecia areata need better inclusion and retention of patients of color.
Search
forLearn
0 / 0 results — no results
Research
5 / 927 resultsresearch An Evaluation of Distal Hair Cortisol Concentrations Collected at Delivery
Distal hair cortisol is not a reliable measure of early pregnancy cortisol levels.
research Secondary Sexual Characteristics and Menstruation in Young Girls
African-American girls tend to start puberty earlier than white girls, possibly due to increased androgen production.
research Comparison Between Melatonin, Melatonin and Photobiomodulation, and Photobiomodulation in the Treatment of Alopecia X in German Spitz Dogs: Clinical, Randomized, Double-Blind, Parallel, Non-Inferiority Protocol
Melatonin and photobiomodulation are effective for treating Alopecia X in German Spitz dogs.
research Multimodal Recruitment for an Internet-Based Pilot Study of Ovulation and Menstruation Health
The study successfully gathered a diverse group of 438 women to understand the prevalence of polycystic ovary syndrome, with most participants recruited online and at community fairs.
Community Join
5 / 36 resultscommunity Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.